Literature DB >> 3373312

Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody.

J A Carrasquillo1, P Sugarbaker, D Colcher, J C Reynolds, J Esteban, G Bryant, A M Keenan, P Perentesis, K Yokoyama, D E Simpson.   

Abstract

The monoclonal antibody B72.3 is a murine IgG1 that is reactive with a wide range of carcinomas while demonstrating little or no reactivity to normal adult tissues. We have shown (27) quantitative analyses demonstrating selective targeting of [131I]B72.3 IgG to metastatic colorectal cancer. We have also shown (28) that (a) B72.3 localization in metastases correlated with the percentage of tumor cells in the biopsy specimen; (b) B72.3 could localize in carcinomas of various degrees of differentiation with best localization in well-differentiated tumors and (c) [131I]B72.3 could penetrate tumor masses, as determined by autoradiographic studies. We report here the various parameters effecting radioimmunoscintigraphy with [131I]B72.3 IgG. Sixteen of 35 patients with colorectal carcinoma had positive scans (without blood-pool subtraction). High circulating TAG-72 antigen levels correlated with positive scans. No dose dependent differences were seen in biodistribution or tumor imaging. The plasma clearance and urinary excretion of [131I]B72.3 and [125I]BL-3 (nonspecific control) were not significantly different. No toxicity was noted. Approximately one-half of patients developed human anti-mouse immune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373312

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody.

Authors:  M B Khazaeli; M N Saleh; T Liu; P M Kaladas; S C Gilman; A F LoBuglio
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

2.  Genetic engineering of high affinity anti-human colorectal tumour mouse/human chimeric antibody.

Authors:  J Xiang; Z Chen
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

3.  Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer.

Authors:  J K Chung; M C Lee; H K Chung; S M Lim; J J Jang; C S Koh
Journal:  Ann Nucl Med       Date:  1995-02       Impact factor: 2.668

4.  Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.

Authors:  J Xiang; J Koropatnick; Y Qi; X Luo; T Moyana; K Li; Y Chen
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

5.  Radioimmunoscintigraphy of CEA/CA 19-9 producing tumors with I-131 labeled monoclonal antibodies.

Authors:  A S Arbab; K Koizumi; G Uchiyama; T Arai; H Eguchi; Y Matsumoto; K Suda
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

6.  High-affinity chimeric anti-(colorectal carcinoma) antibody correlated to enhanced tumor targeting in biodistribution and imaging.

Authors:  Y Qi; G Matte; A Wilkinson; X Jim
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 7.  Monoclonal antibodies in imaging and therapy of colorectal cancer.

Authors:  M K Lange; E W Martin
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

8.  Localization of human sarcoma with radiolabeled monoclonal antibody--a follow-up report.

Authors:  J A Greager; T C Chao; J M Brown; D G Pavel; M J Blend; T K Das Gupta
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.

Authors:  G L Ray; K E Baidoo; K J Wong; M Williams; K Garmestani; M W Brechbiel; D E Milenic
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

Review 10.  Monoclonal antibodies in the management of carcinoma patients.

Authors:  M Roselli; C U Casciani; F Guadagni; O Buonomo; B Iorio; A Diodati; V Vittorini; J W Greiner; D Colcher; J Schlom
Journal:  Med Oncol Tumor Pharmacother       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.